Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa News Ledger.
Press releases published on May 14, 2025
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
GlobeNewswire
·
May 14, 2025
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 mg twice daily cohort in the ongoing …
Entrée Resources Announces Drill Results from Hugo North Extension, Including 260 Metres Grading 4.45% CuEq
GlobeNewswire
·
May 14, 2025
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Entrée Resources Ltd. (TSX:ETG; OTCQB:ERLFF – the “Company” or “Entrée”) is pleased to provide analytical results for one surface diamond drill hole (“DDH”) and six underground DDHs completed …
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer
GlobeNewswire
·
May 14, 2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been dosed …
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
GlobeNewswire
·
May 14, 2025
-- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology ( …
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive …
Highland Copper Announces Completion of Copperwood Metallurgical Drilling and Continued Progress on Detailed Engineering
GlobeNewswire
·
May 14, 2025
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Highland Copper Company Inc. (TSXV: HI; OTCQB: HDRSF) (“Highland” or the “Company”) is pleased to provide an update on recent developments at its 100%-owned Copperwood Project (“Copperwood”) and …
Altimmune to Participate at Two Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the …
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
GlobeNewswire
·
May 14, 2025
Clear Improvement in Patient’s Skin Appearance Observed in Study after 12 weeks Compared to Baseline Key endpoints including Investigator’s Global Assessment (IGA), Modified Ichthyosis Area Severity (M-IASI) and Children’s Dermatology Life Quality Index ( …
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
GlobeNewswire
·
May 14, 2025
VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., May 14, 2025 (GLOBE …
Stallion Uranium Announces Failure to File Cease Trade Order
GlobeNewswire
·
May 14, 2025
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) announces that the British Columbia Securities Commission (the "BCSC"), as the principal regulator of …
Erdene Announces Q1 2025 Results and Provides Bayan Khundii Project Update
GlobeNewswire
·
May 14, 2025
HALIFAX, Nova Scotia, May 14, 2025 (GLOBE NEWSWIRE) -- Erdene Resource Development Corp. (TSX:ERD; MSE:ERDN) ("Erdene" or the "Company") is pleased to announce operating and financial results for the quarter ended March 31, 2025, and to provide an update …
Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy
GlobeNewswire
·
May 14, 2025
WALTHAM, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has submitted a Citizen Petition with the U.S. Food and Drug Administration (FDA) calling on the Agency to evolve from historical approaches to the development …
Benitec Biopharma Releases Third Quarter 2025 Financial Results
GlobeNewswire
·
May 14, 2025
HAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace …
Tisento Highlights Two Venues Advancing Patient-Focused Therapeutic Development for Mitochondrial Diseases
GlobeNewswire
·
May 14, 2025
Tisento to Present at the “Primary Mitochondrial Diseases” Therapeutic Development Workshop Hosted by the Reagan-Udall Foundation for the FDA on May 22, 2025 Tisento to Sponsor the First Externally Led Patient-Focused Drug Development Meeting Dedicated to …
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
GlobeNewswire
·
May 14, 2025
FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show synergistic activity with FHD-909 in combination with …
Ligand to Ring the Nasdaq Opening Bell on May 19, 2025
GlobeNewswire
·
May 14, 2025
JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025. CEO Todd Davis will be joined by members of Ligand’s …
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor …
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
GlobeNewswire
·
May 14, 2025
With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments Anticipate topline data midyear from the Phase 2b clinical trial of BPL-003 in patients with treatment- …
Harfang Makes New Gold Discovery and Drills 7.0 g/t Au Over 18.0 m at Sky Lake, Ontario
GlobeNewswire
·
May 14, 2025
MONTREAL, May 14, 2025 (GLOBE NEWSWIRE) -- Harfang Exploration Inc. (TSX.V: HAR) (“Harfang” or the “Company”) is pleased to announce a new gold discovery and the first batch of results from the maiden 2025 winter diamond drill program (“Winter Drilling”). …
Harfang réalise une nouvelle découverte aurifère et intercepte 7,0 g/t Au sur 18.0 m à Sky Lake, Ontario
GlobeNewswire
·
May 14, 2025
MONTRÉAL, 14 mai 2025 (GLOBE NEWSWIRE) -- Harfang Exploration Inc. (TSX.V: HAR) (“Harfang” ou la “Société”) a le plaisir d’annoncer une nouvelle découverte aurifère ainsi que les premiers résultats de son programme inaugural de forage au diamant de l’hiver …